PLoS ONE (Jan 2013)

Tolerogenic vaccination reduced effector memory CD4 T cells and induced effector memory Treg cells for type I diabetes treatment.

  • Jingyao Zhang,
  • Wenjuan Gao,
  • Xu Yang,
  • Jingjing Kang,
  • Yongliang Zhang,
  • Qirui Guo,
  • Yanxin Hu,
  • Guoliang Xia,
  • Youmin Kang

DOI
https://doi.org/10.1371/journal.pone.0070056
Journal volume & issue
Vol. 8, no. 7
p. e70056

Abstract

Read online

BACKGROUND: Vaccination could induce immune tolerance and protected NOD mice from the development of type I diabetes (T1D). We previously demonstrated that insulin peptide (B9-23) combined with dexamethasone (DEX) stimulated the expansion of antigen specific regulatory T (Treg) cells which in turn effectively prevented T1D in NOD mice. Here, we aimed to investigate the therapeutic effect of tolerogenic vaccination for T1D treatment. METHODOLOGY/PRINCIPAL FINDINGS: The diabetic NOD mice (Blood glucose level ≧250 mg/dl) were treated with B9-23 and DEX twice. The tolerance was restored by blocking maturation of dendritic cells (DCs) and inducing Treg cells in treated NOD mice. Remarkably, the reduction of autoreactive effector memory CD4 T (Tm) cells and the induction of functional effector memory Treg (mTreg) cells contributed to the improvement of T1D in treated NOD mice. CONCLUSIONS/SIGNIFICANCE: Tolerogenic vaccination restored tolerance and ameliorated T1D by suppressing effector CD4 Tm cells and inducing effector mTreg cells. Our findings implicate the potential of tolerogenic vaccination for T1D treatment.